	US 11,872,200 B2
	GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
Daniel L Kaufman, Los Angeles, CA (US); and Jide Tian, Los Angeles, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Mar. 22, 2021, as Appl. No. 17/208,064.
Application 17/208,064 is a division of application No. 16/593,689, filed on Oct. 4, 2019, granted, now 10,952,980.
Application 16/593,689 is a division of application No. 15/786,440, filed on Oct. 17, 2017, granted, now 10,434,078.
Application 15/786,440 is a division of application No. 14/752,487, filed on Jun. 26, 2015, granted, now 9,820,955.
Application 14/752,487 is a division of application No. 13/876,147, granted, now 9,089,531, previously published as PCT/US2011/053732, filed on Sep. 28, 2011.
Claims priority of provisional application 61/433,089, filed on Jan. 14, 2011.
Claims priority of provisional application 61/387,398, filed on Sep. 28, 2010.
Prior Publication US 2021/0205248 A1, Jul. 8, 2021
Int. Cl. A61K 31/197 (2006.01); A61K 31/4465 (2006.01); A61K 45/06 (2006.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01)

CPC A61K 31/197 (2013.01) [A61K 31/4465 (2013.01); A61K 38/2013 (2013.01); A61K 39/0008 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01)]

10 Claims

1. A method of delaying the onset of, and/or slowing the progression of, and/or reducing the severity of Type I diabetes in a mammal, said method comprising coadministering to said mammal:

a first compound comprising gamma-aminobutyric acid (GABA); and an anti-CD3 antibody or fragment thereof;

wherein said first compound and said anti-CD3 antibody or fragment thereof are administered in an amount sufficient to delay the onset of diabetes, and/or slow the progression of diabetes, and/or reduce the severity of Type I diabetes in said mammal.